Circulating tumor-cell detection and capture using microfluidic devices

Laszlo Hajba, András Guttman

MTA-PE Translational Glycomics, MUKKI, University of Pannonia, Veszprem, Hungary
Horváth Laboratory of Bioseparation Sciences, University of Debrecen, Debrecen, Hungary

ARTICLE INFO

Keywords:
Cancer-therapy management
Circulating tumor cell (CTC)
CTC capture
CTC detection
Dielectrophoresis
Early detection
Hydrodynamics
Metastases
Microfluidics
Nanotechnology

ABSTRACT

Circulating tumor cells (CTCs) in the bloodstream are considered good indicators of the presence of a primary tumor or even metastases. CTC capture has great importance in early detection of cancer, especially in identifying novel therapeutic routes for cancer patients by finding personalized druggable targets for the pharmaceutical industry. Recent developments in microfluidics and nanotechnology improved the capabilities of CTC detection and capture, including purity, selectivity and throughput. This article covers the recent technological improvements in microfluidics-based CTC-capture methods utilizing the physical and biochemical properties of CTCs. We critically review the most promising hydrodynamic, dielectrophoretic and magnetic force-based microfluidic CTC-capture devices.

© 2014 Elsevier B.V. All rights reserved.

Contents

1. Introduction ................................................................. 1
2. The hydrodynamic approach to rare-cell capture ........................................ 2
3. Affinity-based methods .................................................... 4
4. Dielectrophoretic capture ................................................ 4
5. Magnetic trapping .......................................................... 5
6. Conclusions and future prospects ........................................ 6
Acknowledgment .......................................................... 7
References ................................................................. 7

1. Introduction

Tumor cells can shed into the bloodstream at a very early stage of primary tumor growth and these so called circulating tumor cells (CTCs) may give rise to metastases at distant parts of the body [1]. Detecting the presence of viable CTCs therefore provides a good indicator for the presence of malignant transformations [2]. Isolation and analysis of CTCs is important to improve understanding of their nature, and their ability to initiate metastases, and for effective development of next-generation cancer therapeutics [3–5].

Primary tumors are usually detected at the stage of clinical symptoms by the non-invasive means of imaging techniques, such as traditional radiography (X-ray), magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound, or with invasive biopsy collection. For example, cells shed from a primary tumor can accumulate in the bone marrow (BM) [6], necessitating invasive BM biopsy to see their presence and possibly to monitor the effect of a therapy. CTC-detection technologies can help substitute an invasive biopsy for a simple blood draw, also referred to as liquid biopsy [7–9].

At present, CTC-detection methods are not routinely used by clinicians to make therapeutic decisions, mostly because of the lack
of randomized data showing that therapies based on the CTC
numbers show improvement in prognosis [7]. The analytical valid-
ity of CTC-detection systems is crucial for their clinical accep-
tance, as emphasized in the guidelines recently published by the
US Food and Drug Administration (FDA) [10]. As of today, the only
FDA-approved CTC-detection method is the CellSearch System [11],
which is based on immunomagnetic detection of EpCAM positive
cells.

The most challenging part of effective CTC analysis is the cell-
capture design because of the extremely low abundance or rare-
event nature of these cells. For example, it is of great clinical
importance to enumerate quantitatively 0–10 CTCs per ml in whole
blood that also contains >10⁶ erythrocytes and >10⁶ leukocytes [12].
For sampling rare events in a large cell population, the following
should be considered:

1. throughput, i.e. the number of cell identification or sorting
   steps per unit time;
2. recovery, in the sense of the number of target cells collect-
ed from the input sample; and,
3. purity, which depends on the number of “interfering” cells
   excluded from the analysis [13].

Microfluidic systems with small sample-volume requirement, fast
processing times, multiplexing capabilities and large surface area-
to-volume ratios offer an option for in-vitro cell sorting, detection
and single-cell analysis [14]. Based on these advantages, various
microfluidic platforms have been developed for rare-cell capture,
including CTCs [15]. Recent progress in microbiotechnology and
nanobiotechnology can also aid the development of more ad-
vanced CTC-detecting microfluidic devices [16].

Molecular profiling of CTCs can provide valuable information
about genetic mutations and can identify therapeutic targets for per-
sonalized treatment [17–19]. For example, in primary breast cancer,
human epidermal growth factor receptor-2 (HER2) is an impor-
tant treatment target, so presence of HER2-positive CTCs could be
a good indication for anti-HER2 treatments. Even in case of a HER2-
negative primary tumor verified by tissue biopsy, it might be rea-
sonable to use anti-HER2 treatment if HER2-positive CTCs are found.

Independent of the HER2 status of the primary tumor, the number
of HER2-positive CTCs usually correlates with decreased disease-
free survival and decreased overall survival [20]. Large prospec-
tive clinical trials have already been running to prove the efficiency
of anti-HER2 therapy based on the presence of HER2-positive CTCs
[21]. Another therapeutic target is the epithelial growth factor re-
ceptor (EGFR) in non-small cell lung cancer (NSCLC) patients.

Maheswaran et al. identified a mutation in EGFR by genotyping of
CTCs that cause drug resistance in NSCLC patients against EGFR-
inhibitor drugs [22]. Monitoring the tumor genotypes during lung-
cancer patient treatment, CTCs may provide information about
possible acquired resistance against EGFR-inhibitor drugs, so as to
help clinicians in therapeutic decision making.

In this article, we review the new advances and the state of the
art of the most commonly used CTC-capture methods for down-
stream analysis utilizing hydrodynamic, dielectrophoretic and mag-
netic forces to provide an adequate number of these important
marker cells for use in biomedical and clinical applications and de-
velopment of next-generation therapeutics.

2. The hydrodynamic approach to rare-cell capture

Hydrodynamic cell-capture methods in microfluidic settings
greatly depend on the interaction between the species of interest
and the microfluidic channel walls, and the sample-fluid matrix. In
this section, we discuss label-free hydrodynamic capture methods
that are based on size, shape and cell deformability. The cell-wall
interaction can be further divided into continuous wall (channels) and
discrete wall (obstacles) [23]. In a continuous wall, the microfluidic channel has a flat surface and the flow fractionation of
cells is controlled by pressure [24] or tuned by electroosmotic flow
[25]. In the discrete wall, the obstacles are usually posts and/or ridges. Through a periodic array of μm-scale posts, with each row of posts
shifted horizontally with respect to the previous row, cells above a
critical size cannot be carried by the net vertical flow but are lat-
erally displaced at each row. This lateral displacement is also af-
fected by the deformability of the cells. The critical size can be

calculated from the geometrical parameters of the posts (i.e. diam-
eter, gap between posts, and row shift) [26]. Based on the dominant forces, hydrodynamic separation can be further classified into laminar-based, inertia-based and biomimetics-

in-based flows [23].

In laminar-flow-based microfluidics where only the viscous force
is dominant (Re < 1), a cell follows a path that goes through its center
of mass. With carefully-designed flow in a pinched segment of the
microchannel, the cells can be positioned in such a way that the cells
of different sizes follow different paths and are consequently sepa-
rated by size [27]. At higher Reynolds number (1 < Re < 100), the in-
ertial force becomes the dominant separation force [28].

Biomimetics-based microfluidic devices have biologically in-
spired structural designs that can mimic physiological processes or
use biological principles (e.g. blood flow in microcirculation). A good
example is a microfluidic device that was developed to separate blood
cells using biomimetics [29]. The microchannels were designed so
that they mimicked microcirculation and enhanced the lateral mi-
gation of leukocytes. The average diameter of leukocytes is in the
range 10–12 μm [29] and the diameter of erythrocytes is 6.2–8.2 μm [30]. The red blood cells (erythrocytes) were concentrated
in the center of the microchannel, while the white blood cells (leu-
kokyes) laterally migrated to near the microchannel walls. The
biomimetics-based microfluidic device can achieve a 34-fold en-
richment of the leukocyte-to-erythrocyte ratio [29].

Microfiltration is another useful technique for size-based rare-
cell trapping. Membrane microfilters are designed with well-
defined pores to restrict passage for cells above a critical size. Similar
to other types of filtration methods, any particulates commensu-
rable with the pore size can cause clogging. The usual size of a CTC
is >8 μm, which is greater than 90–95% of the largest blood-cell pop-
ulation, erythrocytes (red blood cells) [31,32]. Zheng et al. [33]
designed a membrane microfilter with 11.2 μm circular pores and tested
it with a prostate-cancer cell line (LNCaP) diluted in human-blood
samples from healthy donors. With the average size of LNCaP cells
of 17 ± 1.5 μm, the recovery rate of membrane filtration was
87.3 ± 7.0%. An improved 3D microfiltration approach was pre-
sented by the same authors with the goals of minimizing the stress
on the cell membrane and sustaining cell viability with the same
recovery rate [34].

Microcavity arrays represent another special technique for size-
based capture of CTCs, as shown in Fig. 1. The microcavity-based
microfluidic device was tested with peripheral blood from healthy
donors spiked with MCF-7 and SW-620 tumor cells. Microcavity sizes
were varied in the range 8–11 μm. The recovery rates for MCF-7 cells
diameter 22.5 μm remained almost constant with different
microcavity sizes at a level ≥90%. For the smaller tumor cells of SW-
620 (diameter 11.6 μm), the maximum recovery rate of 88% was ob-
tained using the average microcavity diameter of 9.1 μm [35]. A rectan-
gular type of microcavity array was also developed for effective
capture of SCLC cells using microcavities with 5–9 μm width and 30 μm length [36]. For SCLC cells, the recovery rate was ~80%.

Hydrodynamic lifting was recently developed by Geislinger et al.
for blood-cell separation [37]. The principle of the method was the
utilization of non-inertial hydrodynamic cell-wall interaction [i.e.
at very low Reynolds numbers (Re < 1)], no inertial effects occur and
the hydrodynamic lift (as a purely viscous effect) can provide adequate cell separation [38]. As shown in Fig. 2, the cells in the sample flow enter through a smaller inlet channel to the chamber where the sample flow is hydrodynamically focused by a perpendicular sheath flow. The square cross-section of the sheath flow and sample inlets were 110 μm × 110 μm and 110 μm × 30 μm (y- and z- directions), respectively. The main parameters that influenced the lateral lift velocity were cell size and deformability. The cell radius contributed cubically and cell deformability linearly to the lift velocity, respectively. This lab-on-a-chip system design could also separate CTCs from blood samples.

The selectivity of hydrodynamic lifting-based cell sorting was further enhanced by the application of spiral geometry. In this case, the dominant inertial force and a secondary rotational flow-field perpendicular to the original flow direction (Dean flow) cause the smaller particles to migrate in the direction of the outer half of the channel and the bigger particles migrate towards the inner channel wall [39,40]. This technique, referred to as Dean flow field fractionation, can be applied to separate CTCs from blood cells with high selectivity, based on their size differences [41]. Using double spiral geometry (Fig. 3), the separation efficiency at the inner outlet of the microchannel was found to be 98.72% for a binary test mixture of 5-μm and 15-μm diameter polystyrene particles [42]. After the promising test results, experiments were conducted with 20× diluted human blood drawn from healthy volunteers and spiked with HeLa cells (tumor-to-blood cell ratio 8 × 10⁻⁷). At 60 mL/h flow rate, the separation efficiency for HeLa cells was 90.546 ± 3.41% with throughput of 2.5 × 10⁸ cells/min. Please note that the separation efficiency was defined as the ratio of the number of one cell type collected at the desired outlet (the inner outlet for HeLa cells or the middle outlet for blood cells) to the total number of this kind of cell at all outlets.

Fig. 1. Size-selective microcavity array-based CTC-recovery device. (a) CTC detection. (b) Photograph of the size-selective microcavity array. (c) Photograph of the CTC-recovery device equipped with the array. (d) Scanning electron microscope (SEM) image of MCF-7 cells trapped by the microcavity array. The microcavities were 9 μm in size, with a 60 μm pitch. (© American Chemical Society [35]).

Fig. 2. Hydrodynamic lifting-based microfluidic device. Large arrows indicate the fluid flows. Cells separate in the z direction of the microchannel. (© American Institute of Physics [37]).
3. Affinity-based methods

Although recent developments in the field considerably increased the separation efficiency of hydrodynamic label-free methods, the maximum capture yield was still only around 90%. To improve capture efficiency, special microposts were formed by photolithography in the channels of microfluidic devices and coated with CTC-specific antibodies, such as anti-EpCAM [43]. The two essential parameters that determined the efficiency of cell capture in an affinity-coated microfluidic device were:

1. flow velocity, because it influenced the duration of cell–micropost contact; and,
2. low shear force to ensure maximum cell–micropost attachment, which depends on the micropost distribution in the microchannel [44].

A geometrically-enhanced affinity-based microfluidic device reportedly captured 97 ± 3% of spiked LNCaP cells from PBS [45]. The local topographical interaction can be enhanced by 3D nanostructured cell-capture substrates. Densely-packed nanopillars were prepared with diameters of 100–200 nm using wet chemical etching, followed by coating with the relevant antibody (anti-EpCAM). Cell-capture experiments were performed by employing different nanopillar lengths in the range 4–20 μm. It was reported that the capture yield for EpCAM-positive cells increased with nanopillar length [46]. Optimal capture yield was attained when the nanopillar lengths were comparable with the cell-protrusion lengths of the CTCs [47].

To enhance antibody–CTC interaction, a special hydrogel was developed. A degradable alginate biopolymer coating enabled gentle, efficient release of antibody-captured cells from the microfluidic device. The bottom of the microfluidic channel was coated with the antibody (anti-EpCAM)-functionalized alginate biopolymer. PC-3 cells were spiked into whole blood from a healthy donor and captured in the microfluidic device. After the capture, alginate lyase was pushed through the microfluidic channel, degrading the hydrogel (alginate biopolymer) and releasing the captured cells [48]. The advantage of this approach was that this hydrogel coating minimized non-specific interactions and enabled highly efficient release of the isolated cells (99% ± 1%) following hydrogel dissolution without any effect on cell viability.

A good example of the combination of hydrodynamic and affinity-based cell capture was published by Stott et al. [49]. Their herringbone-chip design enabled passive mixing of blood cells through the generation of microvortices that significantly increased the number of interactions between target CTCs and the antibody-coated chip surface. The herringbone chip was tested with the PC-3 prostate cancer cell line. The whole blood from healthy donors was spiked with PC-3 cells at a concentration of 500 cells/mL. The capture efficiency was 91.8 ± 5.2% for the spiked PC-3 cells.

4. Dielectrophoretic capture

Dielectrophoresis (DEP) is a phenomenon by which a subject (e.g. cell) is forced to move by the application of divergent electric field gradients due to polarization forces. DEP forces depend on different factors, such as cell-membrane and cytoplasm-charge properties, and size. The electric field induces charges within the cell, forming dipoles. If the cell is more polarizable than the suspending medium, it is attracted towards the regions of higher electric fields, and the motion is called positive DEP. Conversely, if the cell is less polarizable than the suspending medium, it is repelled from the regions of higher electric field, and the motion is called negative DEP [50,51].

DEP techniques can also be distinguished by microelectrode type. Metallic microelectrodes with various geometries can be used (e.g. interdigitated [52], castellated [53], oblique [54], spiral [55], circular [56], ring shape [57], and wedge shape [58], that are patterned on a microfluidic wafer using conventional lithography techniques).

Contactless DEP (cDEP) was developed for cell manipulation and sorting [59] so that the conventional metallic microelectrodes were replaced by fluidic electrode channels, filled with high-conductivity fluids. Application of this technique, eliminated problems (e.g. bubble formation and electrode-sample contamination) [60] and decreased fabrication costs.

Davis and co-workers recently developed a high-throughput continuous-flow DEP microfluidic device, named ApoStream [61], where an AC electric field was applied to the sample within optimized flow-path regions. The floor of the flow chamber comprised a flexible polyimide film sheet with electroplated copper and gold electrodes. An acrylic sheet formed the ceiling and a gasket the side walls. The sample was injected through a port located at the floor of the flow chamber at the same upstream end as the elution buffer. Cancer cells were collected through another port located downstream from the sample inlet port (Fig. 4).

With the setting shown in Fig. 4, the average recovery of SKOV-3 and MDA-MB-231 cancer cells, spiked into 12 × 10^6 peripheral blood mononuclear cells obtained from normal human-donor blood, was 75.4% ± 3.1% (number of samples was 12) and 71.2% ± 1.6% (number of samples was 6), respectively. These percentage values were much...
higher than in other reports using the DEP method [52] and the viability of the captured MDA-MB-231 cancer cells was greater than 97.1%.

Lee and co-workers developed a high-purity CTC-isolation technique based on optically-induced DEP (ODEP) [62], which featured a sandwich structure with top and bottom layers made of indium-tin-oxide (ITO) glass, and the bottom layer had a photoconductive coating (hydrogenated amorphous silicon). Between these layers, there was a liquid layer containing the sample. An alternating-current (AC) voltage was first applied in the ODEP system to produce a uniform electric field. After optical illumination, electron-hole pairs were generated in the photoconductive layer, causing significant increase in the conductivity of the bottom layer. This phenomenon allowed the applied voltage to drop across the liquid layer, producing a locally non-uniform electric field at the illuminated regions [63]. With this method, the recovery rate was 76–83% for PC-3 cells, and 61–68% for OEC-M1 cells with ~95% viability [62]. The viability of the captured CTCs also depended on the applied voltage and the frequency of the DEP field, so DEP operation conditions needed to be carefully optimized to avoid collection of non-viable cells [64,65]. A low-intensity, intermediate-frequency alternating electric field (100–300 kHz) might have an inhibitory effect on the growth rate of a variety of human-tumor cell lines [66].

5. Magnetic trapping

Magnetic-trapping techniques utilize magnetic particles with magnetic-field manipulation. Magnetic particles are typically sized in the range of several nanometers to a couple of micrometers and they have a magnetic core and a non-magnetic coating that can be chemically modified [15,67]. In microfluidic systems, both permanent magnets and/or electromagnets can be used. Passive magnetic [68] elements or electromagnets [69,70] are usually assembled in the wall of the microchannels to trap the magnetic particles at the surface of the microchannel.

Effective capture of MCF-7 breast-cancer cells in a microfluidic chip with self-assembled protein-coated magnetic beads was demonstrated by Sivagnanam et al. [71]. The beads were patterned in situ inside a sealed microfluidic channel by magnetic-field-assisted electrostatic self-assembly and grafted by 5D10 monoclonal antibodies. The capture efficiency of the system for MCF-7 cells was 85 ± 10%.

Superparamagnetic beads were also utilized for magnetic cell capture. In the so-called Ephesia system, these beads self-assembled in a microfluidic channel into an array of magnetic traps prepared by microcontact printing. This approach combined the advantages of microfluidic cell sorting, notably the application of a well-controlled, flow-activated interaction between cells and beads, and immunomagnetic sorting. The superparamagnetic beads were antibody (anti-EpCAM)-coated for CTC capture [72]. Under a moderate external magnetic field, dipole-dipole interactions between the magnetic bead particles formed chains aligned along the electric field direction forming nanopillar-like structures [73]. The principle of this technology is depicted in Fig. 5. Cell-capture yield reached 94% with this approach.

Another interesting approach is the utilization of magnetophoretic mobility [i.e. the motion of particles in a viscous medium induced by a magnetic field on a particle or cell of magnetic or magnetizable material (e.g. magnetically-labeled cells)] [74]. Murthy and co-workers developed a continuous-flow, magnetophoretic, microfluidic,
rare-cell-capture device with the principle of applying a laminar flow in the y-direction and a magnetic field in the x-direction, so the magnetically-tagged cells moved from the outside sample streams to the center collection stream (Fig. 6) [75]. To test the capability of the set-up, 50 MCF-7 cells were spiked into 1 mL blood from healthy volunteers. The blood samples were then mixed with Dynal MyOne anti-EpCAM-functionalized magnetic beads and applied. The capture efficiency was greater than 85% with purity over 90% [75].

An interesting approach with a negative CTC-enrichment technique was also developed utilizing the combination of viscous flow and magnetic force to facilitate the recovery of unlabeled cells (CTCs) from whole-blood samples obtained from cancer patients [76,77]. The method was based on removal of erythrocytes by lysis followed by the magnetic separation of immunomagnetically-labeled (with CD45 antibody) leukocytes. After the magnetic separation, the remaining cells were considered mostly CTCs.

6. Conclusions and future prospects

Recent advances in nanotechnology and microfluidics have made possible the design and the implementation of highly-reliable CTC-capture platforms with excellent yield and selectivity for the most common types of cancer cell. Capture systems with high throughput, rapid processing times and minimal false-positive rates are highly desirable in the medical and diagnostic fields to monitor progress during cancer therapy and, more importantly, for early cancer detection. Molecular profiling of CTCs can also help to identify new targets and so can aid development of novel therapeutic agents. For wider acceptance, the capabilities of CTC targeting microfluidic detection and capture devices should be demonstrated on a large variety of cancer types. In addition, for proper regulatory approvals, the analytical validity of the CTC assay should be rigorously tested based on Clinical Laboratory Improvement Amendments (CLIA) or Good Laboratory Practice (GLP) standards.

We expect that, in the near future, once such microfluidic CTC detection and capture devices are approved by the regulatory agencies, they will quickly find their way for routine use in personalized therapeutics for cancer patients.

Acknowledgment

The authors gratefully acknowledge the support of the Momentum (Lendulet) grant # 97101 of the Hungarian Academy of Sciences (MTA-PE Translational Glycomics) and TAMOP-4.2.2.A-11/1/KONC-2012-0072.

References